[HTML][HTML] Non-alcoholic fatty liver disease: A patient guideline

SM Francque, G Marchesini, A Kautz, M Walmsley… - JHEP reports, 2021 - Elsevier
SM Francque, G Marchesini, A Kautz, M Walmsley, R Dorner, JV Lazarus, S Zelber-Sagi
JHEP reports, 2021Elsevier
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and
comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many
aspects of the disease are still to be unravelled, which has an important impact on the
information that is given (or not) to patients. Its management requires a close interaction
between patients and their many healthcare providers. It is important for patients to develop …
Summary
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果